FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2343701152> ?p ?o ?g. }

• W2343701152 endingPage "90" @default.
• W2343701152 startingPage "83" @default.
• W2343701152 abstract "Melanoma does not respond meaningfully to systemic chemotherapy. No significant improvement in overall survival has been observed with any therapy in the setting of advanced disease, nor in the adjuvant setting. The most active single drugs achieve 14% to 22% response rates in larger phase II series, and drug combinations have not in general improved true response rates by 15% or more. Experience with recombinant interferon alpha-2 (rIFN alpha 2) administered by a variety of schedules and routes has demonstrated tumor response rates of 12% to 22% in advanced melanoma. Administered combined with chemotherapy, rIFN alpha 2 has improved response rates in some, but not all trials to date. On the basis of increased responsiveness noted to be inversely related to tumor size, IFN alpha has been explored over the past 7 years as an adjuvant to definitive surgery for melanoma. The North Central Cancer Treatment Group (NCCTG) and Eastern Cooperative Oncology Group (ECOG) have recently completed trials of 3 and 12 months' duration of maximal dosages of rIFN alpha 2 in subjects with high-risk resected deep primary or lymph node metastatic melanoma. These randomized controlled studies completed accrual in 1990. The ECOG trial EST 1684 has tested the effect of rIFN alpha 2b, given intravenously daily for 5 days per week for 4 weeks at 20 x 10(6) IU/m2/d, then subcutaneously three times a week at 10 x 10(6) IU/m2/d for 11 months. A series of three analyses is planned for the ECOG trial, and the first of these interim analyses was reported to the ECOG in June, 1990, revealing an encouraging divergence of survival curves that does not achieve statistical significance at this early time. A randomized controlled study of 3 months' duration of rIFN alpha 2a at 12 x 10(6) IU/m2/d intramuscularly three times a week performed by the NCCTG is also in too early a stage to allow definitive conclusions yet. The toxicity of IFN alpha administered at maximum tolerated doses has been significant in terms of constitutional symptoms and organ dysfunction. There have been two instances of fatal toxicity observed in the ECOG study (286 subjects). Consideration of lower, more tolerable dosage regimens has been derived from the desire to evaluate longer periods of IFN alpha 2 therapy, and long-term maintenance treatment with IFN alpha 2 in adjuvant melanoma therapy. In addition, immunologic studies suggest that dosages of 3 x 10(6) IU/m2/d may be more immunologically active in vivo.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2343701152 created "2016-06-24" @default.
• W2343701152 creator A5007239425 @default.
• W2343701152 date "1991-10-01" @default.
• W2343701152 modified "2023-10-06" @default.
• W2343701152 title "Studies of interferons in the therapy of melanoma." @default.
• W2343701152 cites W1487633847 @default.
• W2343701152 cites W1501348451 @default.
• W2343701152 cites W1502286144 @default.
• W2343701152 cites W1907323769 @default.
• W2343701152 cites W1929485758 @default.
• W2343701152 cites W1970734978 @default.
• W2343701152 cites W1975368057 @default.
• W2343701152 cites W1976177466 @default.
• W2343701152 cites W1989360502 @default.
• W2343701152 cites W1991244632 @default.
• W2343701152 cites W1996222068 @default.
• W2343701152 cites W2007736284 @default.
• W2343701152 cites W2011493529 @default.
• W2343701152 cites W2023177577 @default.
• W2343701152 cites W2025936659 @default.
• W2343701152 cites W2028804305 @default.
• W2343701152 cites W2032751495 @default.
• W2343701152 cites W2035566433 @default.
• W2343701152 cites W2047089546 @default.
• W2343701152 cites W2057908608 @default.
• W2343701152 cites W2058187175 @default.
• W2343701152 cites W2066704699 @default.
• W2343701152 cites W2067615306 @default.
• W2343701152 cites W2071754660 @default.
• W2343701152 cites W2073277368 @default.
• W2343701152 cites W2092690255 @default.
• W2343701152 cites W2097841523 @default.
• W2343701152 cites W2120135496 @default.
• W2343701152 cites W2136683349 @default.
• W2343701152 cites W2164675068 @default.
• W2343701152 cites W2173422486 @default.
• W2343701152 cites W2175632971 @default.
• W2343701152 cites W2209896411 @default.
• W2343701152 cites W2285002277 @default.
• W2343701152 cites W2398852224 @default.
• W2343701152 cites W2404730106 @default.
• W2343701152 cites W2406374864 @default.
• W2343701152 cites W2410520767 @default.
• W2343701152 cites W2413986234 @default.
• W2343701152 cites W2414415606 @default.
• W2343701152 cites W2414711602 @default.
• W2343701152 cites W2416720676 @default.
• W2343701152 cites W2430895378 @default.
• W2343701152 cites W2461332013 @default.
• W2343701152 cites W319465161 @default.
• W2343701152 cites W592378983 @default.
• W2343701152 cites W622984185 @default.
• W2343701152 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1948134" @default.
• W2343701152 hasPublicationYear "1991" @default.
• W2343701152 type Work @default.
• W2343701152 sameAs 2343701152 @default.
• W2343701152 citedByCount "25" @default.
• W2343701152 countsByYear W23437011522021 @default.
• W2343701152 crossrefType "journal-article" @default.
• W2343701152 hasAuthorship W2343701152A5007239425 @default.
• W2343701152 hasConcept C121608353 @default.
• W2343701152 hasConcept C126322002 @default.
• W2343701152 hasConcept C141071460 @default.
• W2343701152 hasConcept C143998085 @default.
• W2343701152 hasConcept C162156334 @default.
• W2343701152 hasConcept C168563851 @default.
• W2343701152 hasConcept C203014093 @default.
• W2343701152 hasConcept C2776178377 @default.
• W2343701152 hasConcept C2776694085 @default.
• W2343701152 hasConcept C2777658100 @default.
• W2343701152 hasConcept C2777701055 @default.
• W2343701152 hasConcept C2777863537 @default.
• W2343701152 hasConcept C2777982462 @default.
• W2343701152 hasConcept C2781228144 @default.
• W2343701152 hasConcept C2909179924 @default.
• W2343701152 hasConcept C502942594 @default.
• W2343701152 hasConcept C535046627 @default.
• W2343701152 hasConcept C71924100 @default.
• W2343701152 hasConceptScore W2343701152C121608353 @default.
• W2343701152 hasConceptScore W2343701152C126322002 @default.
• W2343701152 hasConceptScore W2343701152C141071460 @default.
• W2343701152 hasConceptScore W2343701152C143998085 @default.
• W2343701152 hasConceptScore W2343701152C162156334 @default.
• W2343701152 hasConceptScore W2343701152C168563851 @default.
• W2343701152 hasConceptScore W2343701152C203014093 @default.
• W2343701152 hasConceptScore W2343701152C2776178377 @default.
• W2343701152 hasConceptScore W2343701152C2776694085 @default.
• W2343701152 hasConceptScore W2343701152C2777658100 @default.
• W2343701152 hasConceptScore W2343701152C2777701055 @default.
• W2343701152 hasConceptScore W2343701152C2777863537 @default.
• W2343701152 hasConceptScore W2343701152C2777982462 @default.
• W2343701152 hasConceptScore W2343701152C2781228144 @default.
• W2343701152 hasConceptScore W2343701152C2909179924 @default.
• W2343701152 hasConceptScore W2343701152C502942594 @default.
• W2343701152 hasConceptScore W2343701152C535046627 @default.
• W2343701152 hasConceptScore W2343701152C71924100 @default.
• W2343701152 hasIssue "5 Suppl 7" @default.

• next